Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 115
- 试验地点
- 1
- 主要终点
- Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE
研究概览
简要总结
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 14 Years 至 90 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE
时间窗: Retrospective data January 2010 - April 30, 2014
Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE.
次要结局
- Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE(Retrospective data January 2010 - April 30, 2014)
